References
- Ricke J, Wust P, Stohlmann A, Beck A, Cho CH, Pech M, et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 2004; 58: 1496–505. doi: 10.1016/j.ijrobp.2003.09.024
- Ricke J, Wust P, Wieners G, Beck A, Cho CH, Seidensticker M, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol 2004; 15: 1279–86. doi: 10.1097/01.Rvi.0000141343.43441.06
- Seidensticker M, Wust P, Rühl R, Mohnike K, Pech M, Wieners G, et al. Safety margin in irradiation of colorectal liver metastases: assessment of the control dose of micrometastases. Radiat Oncol 2010; 5: 24. doi: 10.1186/1748-717x-5-24
- Ricke J, Mohnike K, Pech M, Seidensticker M, Rühl R, Wieners G, et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78: 479–85. doi: 10.1016/j.ijrobp.2009.09.026
- Wybranski C, Zeile M, Löwenthal D, Fischbach F, Pech M, Röhl FW, et al. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases. Radiat Oncol 2011; 6: 43. doi: 10.1186/1748-717x-6-43
- Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of malignancies in various inner organs − technique, indications, and perspectives. J Contemp Brachytherapy 2016; 8: 251–61. doi: 10.5114/jcb.2016.61068
- Omari J, Drewes R, Orthmer M, Hass P, Pech M, Powerski M. Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, inter-stitial brachytherapy as second-line or salvage therapy. Diagn IntervRradiol 2019; 25: 360–7. doi: 10.5152/dir.2019.18390
- Chow DH, Sinn LH, Ng KK, Lam CM, Yuen J, Fan ST, et al. Radiofrequency ablation for hepatocellular carcinoma and metastatic liver tumors: a comparative study. J Surg Oncol 2006; 94: 565–71. doi: 10.1002/jso.20674
- Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 1992; 159: 591–9. doi: 10.2214/ajr.159.3.1503032
- Dudeck O, Zeile M, Wybranski C, Schulmeister A, Fischbach F, Pech M, et al. Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol 2010; 20: 2699–706. doi: 10.1007/s00330-010-1846-z
- Welsh JS, Kennedy AS, Thomadsen B. Selective internal radiation therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66(2 Suppl): S62–73. doi: 10.1016/j.ijrobp.2005.09.011
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60. doi: 10.1055/s-0030-1247132
- Kim MN, Kim BK, Han KH, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol 2015; 9: 335–48. doi: 10.1586/17474124.2015.959929
- Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90 ± Sorafenib. Hepatology 2013; 58: 1655–66. doi: 10.1002/hep.26487
- Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 2006; 9: 125–32. doi: 10.1053/j.tvir.2007.02.004
- Ludwig JM, Camacho JC, Kokabi N, Xing M, Kim HS. The role of diffusion-weighted imaging (DWI) in Locoregional therapy outcome prediction and response assessment for hepatocellular carcinoma (HCC): the new era of functional imaging biomarkers. Diagnostics 2015; 5: 546–63. doi: 10.3390/diagnostics5040546
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47. doi: 10.1016/j.ejca.2008.10.026
- Hamm B, Thoeni RF, Gould RG, Bernardino ME, Lüning M, Saini S, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994; 190: 417–23. doi: 10.1148/radiology.190.2.8284392
- Ishida K, Tamura A, Kato K, Uesugi N, Osakabe M, Eizuka M, et al. Correlation between CT morphologic appearance and histologic findings in colorectal liver metastasis after preoperative chemotherapy. Abdom Radiol (NY) 2018; 43: 2991–3000. doi: 10.1007/s00261-018-1588-y
- Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622–35. doi: 10.2214/ajr.06.1403
- Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and per-fusion in neurologic disorders. Radiology 1986; 161: 401–7. doi: 10.1148/radiology.161.2.3763909
- Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894–900. doi: 10.1148/radiol.2483071407
- Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol 2009; 48: 1034–43. doi: 10.1080/02841860903099972
- Koh DM, Scurr E, Collins D, Kanber B, Norman A, Leach MO, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007; 188: 1001–8. doi: 10.2214/ajr.06.0601
- Marugami N, Tanaka T, Kitano S, Hirohashi S, Nishiofuku H, Takahashi A, et al. Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging. Cardiovasc Intervent Radiol 2009; 32: 638–46. doi: 10.1007/s00270-009-9532-8
- Schraml C, Schwenzer NF, Clasen S, Rempp HJ, Martirosian P, Claussen CD, et al. Navigator respiratory-triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation-initial results. J Magn Reson Imaging 2009; 29: 1308–16. doi: 10.1002/jmri.21770
- Schmeel FC, Simon B, Luetkens JA, Traber F, Meyer C, Schmeel LC, et al. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. J Cancer Res Clin Oncol 2017; 143: 1531–41. doi: 10.1007/s00432-017-2395-5
- Lahrsow M, Albrecht MH, Bickford MW, Vogl TJ. Predicting treatment response of colorectal cancer liver metastases to conventional lipiodol-based transarterial chemoembolization using diffusion-weighted MR imaging: value of pretreatment apparent diffusion coefficients (ADC) and ADC changes under therapy. Cardiovasc Intervent Radiol 2017; 40: 852–9. doi: 10.1007/s00270-017-1634-0
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–9. doi: 10.1016/j.jclinepi.2007.11.008
- Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172–9. doi: 10.1016/j.ijrobp.2009.07.1700
- Ingenerf MK, Karim H, Fink N, Ilhan H, Ricke J, Treitl KM, et al. Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. Acta Radiol 2022; 63: 877–88. doi: 10.1177/02841851211024004
- Outwater E, Tomaszewski JE, Daly JM, Kressel HY. Hepatic colorectal metastases: correlation of MR imaging and pathologic appearance. Radiology 1991; 180: 327–32. doi: 10.1148/radiology.180.2.2068294
- Curvo-Semedo L, Lambregts DM, Maas M, Beets GL, Caseiro-Alves F, Beets-Tan RG. Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging 2012; 35: 1365–71. doi: 10.1002/jmri.23589
- Liu Z, Fan JM, He C, Li ZF, Xu YS, Li Z, et al. Utility of diffusion weighted imaging with the quantitative apparent diffusion coefficient in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization: a meta-analysis. Cancer Imaging 2020; 20: 3. doi: 10.1186/s40644-019-0282-9